Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linaprazan Dose-Finding Study in GERD Without Erosive Esophagitis
NCT00206284Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- May 2004
- Modality
- Small Molecules
- Countries
- 10
01
Overview
A Phase 2 trial of Linaprazan in gastroesophageal reflux disease (GERD), sponsored by AstraZeneca. Started May 2004; status: completed.
02
Drugs
Linaprazan
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT00206284.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00206284.